Recombinant AAV batch profiling by nanopore sequencing
Posted: 1 February 2025Recombinant AAV vectors are widely used for in vivo gene therapy in all stages ranging from pre-clinical to clinical research, but also several approved therapies. An important quality attribute is vector genome composition, which can be characterized in depth by next generation sequencing. We developed a nanopore sequencing workflow to gather high quality data on vector genome identity, vector truncation hotspots, product related DNA impurities, and in-depth analysis of encapsidated host cell DNA.
A recent peer-reviewed paper in Molecular Therapy Methods & Clinical Development led by Dunker-Seidler, Breunig and colleagues from Ascend Munich confirmed that with the latest quality improvements nanopore data are in full agreement with SMRT™ sequencing data. This means that without sacrificing quality, developers can profit from faster turn-around times and lower rAAV sample consumption.
To learn more about our in-house nanopore sequencing service and how it can benefit your own gene therapy projects please don’t hesitate and get in touch with business@ascend-adv.com.